Skip to main content Back to Top
Advertisement

5/21/2020

Amphetamine Mixed Salts, Immediate-Release Tablets

Products Affected - Description

    • Amphetamine mixed salts immediate release tablet, Mylan, 12.5 mg, bottle, 100 count, NDC 00378-4544-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 15 mg, bottle, 100 count, NDC 00378-4545-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 20 mg, bottle, 100 count, NDC 00378-4546-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 30 mg, bottle, 100 count, NDC 00378-4547-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 5 mg, bottle, 100 count, NDC 00378-4541-01
    • Amphetamine mixed salts immediate release tablet, Mylan, 7.5 mg, bottle, 100 count, NDC 00378-4542-01
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 10 mg, bottle, 100 count, NDC 57664-0643-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 12.5 mg, bottle, 100 count, NDC 57664-0644-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 15 mg, bottle, 100 count, NDC 57664-0645-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 20 mg, bottle, 100 count, NDC 57664-0646-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 30 mg, bottle, 100 count, NDC 57664-0647-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 5 mg, bottle, 100 count, NDC 57664-0641-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Sun Pharma, 7.5 mg, bottle, 100 count, NDC 57664-0642-08 - discontinued
    • Amphetamine mixed salts immediate release tablet, Zydus, 10 mg, bottle, 100 count, NDC 68382-0952-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 12.5 mg, bottle, 100 count, NDC 68382-0953-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 15 mg, bottle, 100 count, NDC 68382-0954-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 20 mg, bottle, 100 count, NDC 68382-0955-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 30 mg, bottle, 100 count, NDC 68382-0956-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 5 mg, bottle, 100 count, NDC 68382-0950-01
    • Amphetamine mixed salts immediate release tablet, Zydus, 7.5 mg, bottle, 100 count, NDC 68382-0951-01

Reason for the Shortage

    • Aurobindo refuses to provide updated availability information.
    • Sun Pharma discontinued amphetamine mixed salts in 2019.
    • Zydus did not provide a reason for the shortage.
    • Mylan did not provide a reason for the shortage
    • Teva has brand name Adderall and generic amphetamine mixed salts available.
    • Mallinckrodt has amphetamine mixed salts available.

Available Products

    • Adderall immediate release tablet, Teva, 10 mg, bottle, 100 count, NDC 57844-0110-01
    • Adderall immediate release tablet, Teva, 12.5 mg, bottle, 100 count, NDC 57844-0112-01
    • Adderall immediate release tablet, Teva, 15 mg, bottle, 100 count, NDC 57844-0115-01
    • Adderall immediate release tablet, Teva, 20 mg, bottle, 100 count, NDC 57844-0120-01
    • Adderall immediate release tablet, Teva, 30 mg, bottle, 100 count, NDC 57844-0130-01
    • Adderall immediate release tablet, Teva, 5 mg, bottle, 100 count, NDC 57844-0105-01
    • Adderall immediate release tablet, Teva, 7.5 mg, bottle, 100 count, NDC 57844-0117-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 10 mg, bottle, 100 count, NDC 00406-8892-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 15 mg, bottle, 100 count, NDC 00406-8885-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 20 mg, bottle, 100 count, NDC 00406-8893-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 30 mg, bottle, 100 count, NDC 00406-8894-01
    • Amphetamine mixed salts immediate release tablet, Mallinckrodt, 5 mg, bottle, 100 count, NDC 00406-8891-01
    • Amphetamine mixed salts immediate release tablet, Teva, 10 mg, bottle, 100 count, NDC 00555-0972-02
    • Amphetamine mixed salts immediate release tablet, Teva, 12.5 mg, bottle, 100 count, NDC 00555-0776-02
    • Amphetamine mixed salts immediate release tablet, Teva, 15 mg, bottle, 100 count, NDC 00555-0777-02
    • Amphetamine mixed salts immediate release tablet, Teva, 20 mg, bottle, 100 count, NDC 00555-0973-02
    • Amphetamine mixed salts immediate release tablet, Teva, 30 mg, bottle, 100 count, NDC 00555-0974-02
    • Amphetamine mixed salts immediate release tablet, Teva, 5 mg, bottle, 100 count, NDC 00555-0971-02
    • Amphetamine mixed salts immediate release tablet, Teva, 7.5 mg, bottle, 100 count, NDC 00555-0775-02

Estimated Resupply Dates

    • Mylan has amphetamine mixed salts 5 mg, 7.5 mg, 10 mg, 12.5mg, 15 mg, 20 mg, and 30 mg immediate release tablets on back order and the company cannot estimate a release date.
    • Zydus has amphetamine mixed salts presentations on allocation.

Updated

Updated May 21, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 20, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.